Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Uterine Fibroid Treatment Devices Market
The global uterine fibroid treatment devices market was valued at USD 8,477.4 million in 2025 and is projected to reach USD 15,913.25 million by 2035, expanding at a CAGR of 6.5% over the forecast period. Growth is driven by rising prevalence of uterine fibroids, increasing adoption of minimally invasive procedures, and technological advancements in ablation and embolization devices. Regulatory approvals for novel therapies and expanding healthcare infrastructure in emerging markets further support market expansion.
However, high procedural costs and reimbursement challenges in low-income regions may temper growth.
Market size
Growth trajectory through 2035
Uterine Fibroid Treatment Devices Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2026 May 2026
- FDA approval of a novel HIFU device for uterine fibroid treatment, expanding non-invasive treatment options.
-
2026 March 2026
- Launch of a next-generation cryoablation system by a leading medical device manufacturer, enhancing procedural precision.
-
2026 January 2026
- Strategic partnership announced between a biotechnology firm and a healthcare provider to expand access to uterine fibroid treatments in underserved regions.
Emerging opportunities added
- Expansion in emerging markets Rapidly growing healthcare infrastructure and increasing healthcare expenditure in regions such as Asia-Pacific and Latin America present opportunities for market expansion. Rising demand for advanced treatment options in these regions supports growth.
- Development of non-invasive and outpatient procedures Advances in non-invasive technologies, such as focused ultrasound and embolization, are enabling outpatient treatment options, reducing hospital stays and healthcare costs. These innovations align with patient preference for less invasive interventions.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $8.48 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High procedural costs and reimbursement challenges
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
May 2026: FDA approval of a novel HIFU device for uterine fibroid treatment, expanding non-invasive treatment options
+2 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 116-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Uterine Fibroid Treatment Devices Market today ($8.48 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of Ablation Devices, Hysterectomy Devices, Myomectomy Devices and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Symptomatic Uterine Fibroids, Abnormal Uterine Bleeding, Pelvic Pain applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Medtronic plc, Stryker Corporation, Boston Scientific Corporation and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of uterine fibroids) and top restraints (led by High procedural costs and reimbursement challenges), with quantified CAGR impact?
- What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of uterine fibroids Increasing incidence of uterine fibroids globally, particularly among women of reproductive age, is driving demand for effective treatment solutions. Demographic trends and improved diagnostic capabilities contribute to higher detection rates.
- Growth of minimally invasive procedures Adoption of minimally invasive techniques such as laparoscopic myomectomy, hysteroscopic resection, and image-guided ablation is expanding due to benefits including reduced recovery times and lower complication rates compared to open surgery.
- Technological advancements in ablation devices Innovations in energy-based ablation technologies, including microwave, cryoablation, and high-intensity focused ultrasound (HIFU), are improving procedural efficacy and patient outcomes, supporting market growth.
Restraints
Holding it back
- High procedural costs and reimbursement challenges The upfront costs of advanced uterine fibroid treatment devices and associated procedures can limit accessibility, particularly in price-sensitive markets. Reimbursement policies vary by region, affecting adoption rates.
- Limited awareness and physician training In some regions, limited awareness of minimally invasive and non-invasive treatment options among healthcare providers and patients may restrict market growth. Training requirements for new technologies can also delay adoption.
- Regulatory and safety concerns Stringent regulatory requirements for medical device approvals and ongoing safety monitoring can slow market entry for innovative technologies. Concerns regarding long-term outcomes and potential complications may also impact adoption.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of uterine fibroids | +2.9% | Global | 2025–2035 |
| Growth of minimally invasive procedures | +1.8% | Global | 2025–2035 |
| Technological advancements in ablation devices | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High procedural costs and reimbursement challenges | −1.2% | Global | 2025–2029 |
| Limited awareness and physician training | −0.8% | Global | 2025–2029 |
| Regulatory and safety concerns | −0.6% | Global | 2025–2029 |
Total 36 Ablation Devices 22% Hysterectomy Dev 19% Myomectomy Devic 17% Embolization Dev 14% MRgFUS Devices 11% Cryoablation Dev 8% Microwave Ablati 6% HIFU Devices 3% The uterine fibroid treatment devices market is segmented by technology, mode of treatment, and region. Key technologies include ablation, hysterectomy, myomectomy, and embolization, while treatment modes range from invasive to non-invasive approaches.
Revenue share by type · 2025 base year
% OF $8.48 BN UTERINE FIBROID TREATMENT DEVICES MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $8.48 Bn Uterine Fibroid Treatment Devices Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Ablation Devices
-
Hysterectomy Devices
-
Myomectomy Devices
-
Embolization Devices
-
MRgFUS Devices
-
Cryoablation Devices
-
Microwave Ablation Devices
-
HIFU Devices
By application
-
Symptomatic Uterine Fibroids
-
Abnormal Uterine Bleeding
-
Pelvic Pain
-
Infertility
-
Pressure Symptoms (e.g
-
urinary frequency
-
Bulk Symptoms (e.g
-
abdominal distension
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $8.48 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~42.2% in 2025. The region is a major market for uterine fibroid treatment devices, driven by high healthcare expenditure, advanced healthcare infrastructure, and strong presence of key industry players
Per-region detail
-
North America
The region is a major market for uterine fibroid treatment devices, driven by high healthcare expenditure, advanced healthcare infrastructure, and strong presence of key industry players
-
Europe
Growth is supported by increasing adoption of minimally invasive procedures and favorable reimbursement policies, though regulatory complexity may pose challenges
-
Asia-Pacific
Rapidly expanding healthcare infrastructure, rising disposable incomes, and increasing awareness of minimally invasive treatments are driving market growth, particularly in China and India
-
Latin America
Market growth is supported by improving healthcare access and rising prevalence of uterine fibroids, though economic constraints and regulatory hurdles may limit adoption
-
Middle East & Africa
Increasing healthcare investments and rising demand for advanced treatment options are contributing to market growth, though limited infrastructure and regulatory challenges remain barriers
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The uterine fibroid treatment devices market is moderately concentrated, with a mix of multinational corporations and specialized medical technology firms competing for market share. Innovation and strategic partnerships are key differentiators.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Medtronic plc
Rank 01Share est. ~16%Revenue $32B FYHQ IE · Dublin -
Stryker Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Zimmer Biomet Holdings
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Edwards Lifesciences
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Intuitive Surgical
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Uterine Fibroid Treatment Devices Market in 2025?
The Uterine Fibroid Treatment Devices Market is estimated at approximately $8.48 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 6.50% CAGR from 2025 to 2035, reaching $15.92 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 42.2% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Ablation leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson MedTech, Zimmer Biomet Holdings, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of uterine fibroids. Increasing incidence of uterine fibroids globally, particularly among women of reproductive age, is driving demand for effective treatment solutions. Demographic trends and improved diagnostic capabilities contribute to higher detection rates.
-
What are the main restraints?
The primary restraint is High procedural costs and reimbursement challenges. The upfront costs of advanced uterine fibroid treatment devices and associated procedures can limit accessibility, particularly in price-sensitive markets. Reimbursement policies vary by region, affecting adoption rates.
-
What are the most recent developments?
Recent notable events include: 2026: May 2026: FDA approval of a novel HIFU device for uterine fibroid treatment, expanding non-invasive treatment options; 2026: March 2026: Launch of a next-generation cryoablation system by a leading medical device manufacturer, enhancing procedural precision; 2026: January 2026: Strategic partnership announced between a biotechnology firm and a healthcare provider to expand access to uterine fibroid treatments in underserved regions. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Uterine Fibroid Treatment Devices Market is projected to reach $15.92 Bn by 2035, up from $8.48 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.